Per thor Straten

Research output

Research output per year 1994 2009 2010 2011 2016 2018 2020

• 52 Journal article
• 4 Conference abstract in journal
• 4 Letter
• 4 Review
• 4 More
  • 3 Comment/debate
  • 1 Book chapter

Research output per year

Research output per year

Search results

• 2020

  TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting

  Peeters, M. J. W., Rahbech, A. & thor Straten, P., 1 Feb 2020, In: Cancer Immunology, Immunotherapy.

  Research output: Contribution to journal › Review › peer-review

  • Tumor Microenvironment 100%
  • T-Lymphocytes 59%
  • c-Mer Tyrosine Kinase 58%
  • Cellular Microenvironment 40%
  • Protein S 39%
  7 Citations (Scopus)
• 2019

  Actively personalized vaccination trial for newly diagnosed glioblastoma

  Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., thor Straten, P., Martínez-Ricarte, F., Ponsati, B., Okada, H., Lassen, U., Admon, A., Ottensmeier, C. H., Ulges, A., Kreiter, S., von Deimling, A., & 44 othersSkardelly, M., Migliorini, D., Kroep, J. R., Idorn, M., Rodon, J., Piró, J., Poulsen, H. S., Shraibman, B., McCann, K., Mendrzyk, R., Löwer, M., Stieglbauer, M., Britten, C. M., Capper, D., Welters, M. J. P., Sahuquillo, J., Kiesel, K., Derhovanessian, E., Rusch, E., Bunse, L., Song, C., Heesch, S., Wagner, C., Kemmer-Brück, A., Ludwig, J., Castle, J. C., Schoor, O., Tadmor, A. D., Green, E., Fritsche, J., Meyer, M., Pawlowski, N., Dorner, S., Hoffgaard, F., Rössler, B., Maurer, D., Weinschenk, T., Reinhardt, C., Huber, C., Rammensee, H. G., Singh-Jasuja, H., Sahin, U., Dietrich, P. Y. & Wick, W., 2019, In: Nature. 565, 7738, p. 240-245 6 p.

  Research output: Contribution to journal › Letter › peer-review

  • Glioblastoma 100%
  • Vaccination 81%
  • Vaccines 76%
  • Glioma 56%
  • HLA Antigens 41%
  238 Citations (Scopus)

• Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome

  Hu, T., Buus, T. B., Krejsgaard, T., Nansen, A., Lundholt, B. K., Spee, P., Fredholm, S., Petersen, D. L., Blümel, E., Gluud, M., Monteiro, M. N., Willerslev-Olsen, A., Andersen, M. H., Straten, P. T., Met, Ö., Stolearenco, V., Fogh, H., Gniadecki, R., Nastasi, C., Litman, T., & 3 othersWoetmann, A., Gjerdrum, L. M. R. & Ødum, N., 1 Aug 2019, In: OncoTarget. 10, 47, p. 4894-4906 13 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • T-Lymphocytes 100%
  • Interleukin-9 58%
  • Voltage-Gated Potassium Channels 53%
  • Cytokine Receptors 48%
  • Annexin A5 45%
  1 Citation (Scopus)

• MERTK Acts as a costimulatory receptor on human cd8 t cells

  Peeters, M. J. W., Dulkeviciute, D., Draghi, A., Ritter, C., Rahbech, A., Skadborg, S. K., Seremet, T., Simoes, A. M. C., Martinenaite, E., Halldorsdottir, H. R., Andersen, M. H., Olofsson, G. H., Svane, I. M., Rasmussen, L. J., Met, O., Becker, J. C., Donia, M., Desler, C. & Straten, P. T., 2019, In: Cancer Immunology Research. 7, 9, p. 1472-1484 13 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • c-Mer Tyrosine Kinase 100%
  • T-Lymphocytes 26%
  • Tumor-Infiltrating Lymphocytes 23%
  • Receptor Protein-Tyrosine Kinases 6%
  • Antigen-Presenting Cells 6%
  13 Citations (Scopus)

• T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients

  Viborg, N., Ramskov, S., Andersen, R. S., Sturm, T., Fugmann, T., Bentzen, A. K., Rafa, V. M., Straten, P. T., Svane, I. M., Met, Ö. & Hadrup, S. R., 2 Dec 2019, In: OncoImmunology. 8, 12, 11 p., 1663107.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • HLA-A*02:01 antigen 100%
  • Breast Neoplasms 69%
  • Antigens 69%
  • T-Lymphocytes 67%
  • Immunotherapy 57%
  3 Citations (Scopus)

  25 Downloads (Pure)
• 2018

  Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model

  Idorn, M., Skadborg, S. K., Kellermann, L., Halldórsdóttir, H. R., Holmen Olofsson, G., Met, Ö. & thor Straten, P., 2018, In: OncoImmunology. 7, 8, 10 p., e1450715.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Chemokine Receptors 100%
  • Heterografts 80%
  • Melanoma 74%
  • T-Lymphocytes 55%
  • Cell- and Tissue-Based Therapy 30%
  18 Citations (Scopus)

• Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site

  Idorn, M. & Thor Straten, P., 17 Aug 2018, In: Cells. 7, 8, p. 1-19 108.

  Research output: Contribution to journal › Review › peer-review

  • Chemokine Receptors 100%
  • Effector 97%
  • Exercise 57%
  • T-Lymphocytes 55%
  • Neoplasms 28%

• Genetically engineered cell factories produce glycoengineered vaccines that target antigen-presenting cells and reduce antigen-specific T-cell reactivity

  Mathiesen, C. B. K., Carlsson, M. C., Brand, S., Möller, S. R., Idorn, M., Straten, P. T., Pedersen, A. E., Dabelsteen, S., Halim, A., Würtzen, P. A., Brimnes, J., Ipsen, H., Petersen, B. L. & Wandall, H. H., Dec 2018, In: Journal of Allergy and Clinical Immunology. 142, 6, p. 1983-1987

  Research output: Contribution to journal › Letter › peer-review

  6 Citations (Scopus)

• Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

  Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., López-Larrea, C., Hilf, N., Kuttruff, S., Song, C., Britten, C., Castle, J., Kreiter, S., Frenzel, K., Tatagiba, M., Tabatabai, G., Dietrich, P-Y., Dutoit, V., Wick, W., Platten, M., & 17 othersWinkler, F., von Deimling, A., Kroep, J., Sahuquillo, J., Martinez-Ricarte, F., Rodon, J., Lassen, U., Ottensmeier, C., van der Burg, S. H., Thor Straten, P., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H-G., Sahin, U., Singh, H. & Admon, A., Nov 2018, In: Molecular and Cellular Proteomics. 17, 11, p. 2132-2145 14 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Neoplasm Antigens 100%
  • Glioblastoma 92%
  • Plasma 57%
  • Peptide 54%
  • Peptides 49%
  12 Citations (Scopus)

• Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction

  Idorn, M., Olsen, M., Halldórsdóttir, H. R., Skadborg, S. K., Pedersen, M., Høgdall, C., Høgdall, E., Met, Ö. & thor Straten, P., 3 Apr 2018, In: OncoImmunology. 7, 4, 12 p., e1412029.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor Microenvironment 100%
  • Ascites 95%
  • Ovarian Neoplasms 87%
  • Lymphocytes 66%
  • Chemokine Receptors 39%
  9 Citations (Scopus)

  57 Downloads (Pure)

• Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations

  Rius, C., Attaf, M., Tungatt, K., Bianchi, V., Legut, M., Bovay, A., Donia, M., Thor Straten, P., Peakman, M., Svane, I. M., Ott, S., Connor, T., Szomolay, B., Dolton, G. & Sewell, A. K., 1 Apr 2018, In: The Journal of Immunology. 200, 7, p. 2263-2279

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Histocompatibility Antigens Class I 100%
  • Antigens 53%
  • T-Lymphocytes 52%
  • Peptides 44%
  • Population 33%
  35 Citations (Scopus)

  39 Downloads (Pure)

• The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

  Holmstrom, M. O., Martinenaite, E., Ahmad, S. M., Met, O., Friese, C., Kjaer, L., Riley, C. H., Straten, P. T., Svane, I. M., Hasselbalch, H. C. & Andersen, M. H., 1 Feb 2018, In: Leukemia. 32, 2, p. 429-437

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Calreticulin 100%
  • Exons 59%
  • T-Lymphocytes 44%
  • Mutation 40%
  • Neoplasms 23%
  47 Citations (Scopus)
• 2017

  Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

  Donia, M., Harbst, K., van Buuren, M., Kvistborg, P., Lindberg, M. F., Andersen, R., Idorn, M., Munir Ahmad, S., Ellebæk, E., Mueller, A., Fagone, P., Nicoletti, F., Libra, M., Lauss, M., Hadrup, S. R., Schmidt, H., Andersen, M. H., Thor Straten, P., Nilsson, J. A., Schumacher, T. N., & 3 othersSeliger, B., Jönsson, G. & Svane, I. M., 1 Sept 2017, In: Cancer Research. 77, 17, p. 4562-4566 5 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Antigens 100%
  • Immunotherapy 51%
  • Neoplasms 50%
  • Recurrence 45%
  • Antigen Presentation 42%
  27 Citations (Scopus)

• Exercise and cancer: from “healthy” to “therapeutic”?

  Idorn, M. & thor Straten, P., May 2017, In: Cancer Immunology, Immunotherapy. 66, 5, p. 667-671 5 p.

  Research output: Contribution to journal › Review › peer-review

  • Exercise 100%
  • Neoplasms 49%
  • Patient Reported Outcome Measures 28%
  • Gonadal Steroid Hormones 27%
  • Body Composition 25%
  30 Citations (Scopus)

  89 Downloads (Pure)

• Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016

  Ascierto, P. A., Agarwala, S. S., Ciliberto, G., Demaria, S., Dummer, R., Duong, C. P. M., Ferrone, S., Formenti, S. C., Garbe, C., Halaban, R., Khleif, S., Luke, J. J., Mir, L. M., Overwijk, W. W., Postow, M., Puzanov, I., Sondel, P., Taube, J. M., Straten, P. T., Stroncek, D. F., & 3 othersWargo, J. A., Zarour, H. & Thurin, M., 16 Nov 2017, In: Journal of Translational Medicine. 15, 31 p., 236.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Melanoma 100%
  • Immunotherapy 26%
  • Therapeutics 19%
  • Tumor-Infiltrating Lymphocytes 19%
  • T-Lymphocytes 18%
  14 Citations (Scopus)

  78 Downloads (Pure)

• Therapy of solid cancers using T cells and running shoes

  Straten, P. T., 2017, In: Journal of Translational Medicine. 15, S1, 1 p., K6.

  Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

  • Shoes 100%
  • Running 85%
  • T-Lymphocytes 50%
  • Neoplasms 26%
  • Exercise 16%
• 2016

  Cancer immunotherapy: From the lab to clinical applications - Potential impact on cancer centres' organisation

  Cairns, L., Aspeslagh, S., Anichini, A., Kyte, J. A., Blank, C., Ascierto, P. A., Rekers, N., thor Straten, E. P. & Awada, A., 9 Nov 2016, In: ecancermedicalscience. 10, 691.

  Research output: Contribution to journal › Journal article › Communication

  • Immunotherapy 100%
  • Organizations 95%
  • Neoplasms 36%
  • Immune System 25%
  • Belgium 18%
  73 Downloads (Pure)

• Exercise: A new role for an old tool

  Idorn, M. & thor Straten, E. P., 3 Jul 2016, In: Molecular & Cellular Oncology. 3, 4, e1163005.

  Research output: Contribution to journal › Comment/debate › Research

  • Neoplasms 100%
  • Growth 39%
  • Incidence 37%
  2 Citations (Scopus)

• GTn repeat polymorphism in heme oxygenase-1 (HO-1) correlates with clinical outcome after myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation

  Køllgaard, T., Kornblit, B., Petersen, J., Klausen, T. W., Mortensen, B. K., Brændstrup, P., Sengeløv, H., Høgdall, E., Müller, K., Vindeløv, L., Andersen, M. H. & thor Straten, E. P., Dec 2016, In: PLoS ONE. 11, 12, 8 p., e0168210.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Oxygenases 100%
  • cell transplantation 70%
  • Transplantation 68%
  • heme oxygenase (biliverdin-producing) 68%
  • transplantation 61%
  5 Citations (Scopus)

  54 Downloads (Pure)

• Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes

  Bentzen, A. K., Marquard, A. M., Lyngaa, R., Saini, S. K., Ramskov, S., Donia, M., Such, L., Furness, A. J. S., McGranahan, N., Rosenthal, R., thor Straten, E. P., Szallasi, Z., Svane, I. M., Swanton, C., Quezada, S. A., Jakobsen, S. N., Eklund, A. C. & Hadrup, S. R., Oct 2016, In: Nature Biotechnology. 34, 10, p. 1037-1045 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • T-cells 100%
  • Antigens 90%
  • Peptides 88%
  • DNA 69%
  • Major Histocompatibility Complex 68%
  130 Citations (Scopus)

• Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

  Andersen, R., Donia, M., Ellebæk, E., Borch, T. H., Kongsted, P., Iversen, T. Z., Hølmich, L. R., Hendel, H. W., Met, Ö., Andersen, M. H., Thor Straten, E. P. & Svane, I. M., 1 Aug 2016, In: Clinical Cancer Research. 22, 15, p. 3734-3745 12 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Cell- and Tissue-Based Therapy 74%
  • Interleukin-2 70%
  • Melanoma 65%
  • Adoptive Transfer 38%
  128 Citations (Scopus)

• mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma

  Borch, T. H., Engell-Noerregaard, L., Iversen, T. Z., Ellebaek, E., Met, Ö., Hansen, M., Andersen, M. H., thor Straten, E. P. & Svane, I. M., 1 Sept 2016, In: OncoImmunology. 5, 9, 12 p., e1207842.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Combined Vaccines 100%
  • Cyclophosphamide 68%
  • Dendritic Cells 65%
  • Melanoma 61%
  • Messenger RNA 41%
  20 Citations (Scopus)

• Targetless T cells in cancer immunotherapy

  thor Straten, E. P. & Garrido, F., 19 Apr 2016, In: Journal for ImmunoTherapy of Cancer. 4, 1, 5 p., 23.

  Research output: Contribution to journal › Comment/debate › Research › peer-review

  • Immunotherapy 100%
  • T-Lymphocytes 70%
  • Neoplasms 36%
  • Down-Regulation 11%
  • Tumor-Infiltrating Lymphocytes 10%
  21 Citations (Scopus)

  98 Downloads (Pure)

• The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma

  Fredholm, S., Litvinov, I. V., Mongan, N. P., Schiele, S., Willerslev-Olsen, A., Petersen, D. L., Krejsgaard, T., Sibbesen, N., Nastasi, C., Bonefeld, C. M., Persson, J. L., thor Straten, E. P., Andersen, M. H., Koralov, S. B., Wasik, M. M., Geisler, C., Sasseville, D., Andersen, A. W. & Ødum, N., 2016, In: Journal of Investigative Dermatology. 136, 4, p. 866-869 4 p.

  Research output: Contribution to journal › Comment/debate › Research › peer-review

  3 Citations (Scopus)

• Transfection of tumor-infiltrating T cells with mRNA encoding CXCR2

  Idorn, M., thor Straten, E. P., Svane, I. M. & Met, Ö., 2016, Synthetic mRNA: Production, Introduction Into Cells, and Physiological Consequences. Rhoads, R. E. (ed.). Springer, Vol. 1428. p. 261-276 16 p. (Methods in Molecular Biology, Vol. 1428).

  Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Transfection 90%
  • T-Lymphocytes 64%
  • Messenger RNA 59%
  • Neoplasms 33%
  8 Citations (Scopus)

• Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution

  Pedersen, L., Idorn, M., Olofsson, G. H., Lauenborg, B., Nookaew, I., Hansen, R. H., Johannesen, H. H., Becker, J. C., Pedersen, K. S., Dethlefsen, C., Nielsen, J., Gehl, J., Pedersen, B. K., Straten, P. T. & Højman, P., 8 Mar 2016, In: Cell Metabolism. 23, 3, p. 554-562

  Research output: Contribution to journal › Letter › peer-review

  • Running 100%
  • Epinephrine 89%
  • Natural Killer Cells 88%
  • Interleukin-6 73%
  • Growth 48%
  290 Citations (Scopus)
• 2015

  Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes

  Køllgaard, T., Ugurel-Becker, S., Idorn, M., Andersen, M. H., Becker, J. C. & thor Straten, E. P., 15 Jul 2015, In: P L o S One. 10, 7, 14 p., e0131934.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Epitopes 100%
  • Correlate 97%
  • T-cells 91%
  • Peptides 87%
  • Vaccines 84%
  8 Citations (Scopus)
• 2012

  Characterization and comparison of "Standard" and "Young" tumor infiltrating lymphocytes for adoptive cell therapy at a Danish Translational Research Institution

  Donia, M., Junker, N., Ellebaek, E., Andersen, M. H., Straten, P. T. & Svane, I. M., Feb 2012, In: Scandinavian Journal of Immunology. 75, 2, p. 157-167 11 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Translational Medical Research 89%
  • Cell- and Tissue-Based Therapy 74%
  • Interleukin-2 12%
  • Melanoma 11%
  48 Citations (Scopus)

• Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures

  Junker, N., Kvistborg, P., Køllgaard, T., Straten, P. T., Andersen, M. H. & Svane, I. M., 2012, In: Cellular Immunology. 273, 1, p. 1-9 9 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Neoplasm Antigens 83%
  • Squamous Cell Carcinoma of Head and Neck 65%
  • Melanoma 49%
  • T-Lymphocytes 48%
  19 Citations (Scopus)
• 2011

  A potential role of indoleamine 2,3-dioxygenase-specific T cells in leishmania vaccination

  thor Straten, P. & Andersen, M. H., 1 Aug 2011, In: Journal of Infectious Diseases. 204, 3, p. 488-9 2 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  3 Citations (Scopus)

• Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer

  Junker, N., Andersen, M. H., Wenandy, L., Dombernowsky, S. L., Kiss, K., Sørensen, C. H., Therkildsen, M. H., Buchwald, C. V., Andersen, E., Straten, P. T., Svane, I. M. & Andersen, M. H., Aug 2011, In: Cytotherapy. 13, 7, p. 822-34

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Adoptive Transfer 90%
  • Squamous Cell Carcinoma of Head and Neck 87%
  • T-Lymphocytes 48%
  • T-Cell Antigen Receptor 16%
  27 Citations (Scopus)

• Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2

  Bjoern, J., Brimnes, M. K., Andersen, M. H., Straten, P. T. & Svane, I. M., Mar 2011, In: Scandinavian Journal of Immunology. 73, 3, p. 222-33 12 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Regulatory T-Lymphocytes 100%
  • Dendritic Cells 90%
  • Interleukin-2 89%
  • Melanoma 83%
  • Vaccination 80%
  16 Citations (Scopus)

• Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application

  Junker, N., Thor Straten, P., Andersen, M. H. & Svane, I. M., 2011, In: Journal of Skin Cancer. 2011, 574695, 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Melanoma 65%
  • Clinical Trials 20%
  • Adoptive Transfer 18%
  • Neoplasm Antigens 16%

• HLA-A2-restricted survivin-derived T-cell responses

  Straten, P. T. & Andersen, M. H., 6 Dec 2011, In: Vaccine. 29, 52, p. 9582

  Research output: Contribution to journal › Letter › peer-review

• Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors

  Andersen, R. S., Sørensen, R. B., Ritter, C., Svane, I. M., Becker, J. C., thor Straten, P. & Andersen, M. H., Feb 2011, In: Cancer Immunology, Immunotherapy. 60, 2, p. 227-34 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Cyclin B1 100%
  • HLA-A2 Antigen 73%
  • Epitopes 64%
  • Tissue Donors 59%
  • Peptides 48%
  6 Citations (Scopus)

• Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α

  Riley, C. H., Jensen, M. K., Brimnes, M. K., Hasselbalch, H. C., Bjerrum, O. W., Straten, P. T. & Svane, I. M., 25 Aug 2011, In: Blood. 118, 8, p. 2170-3 4 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Hydroxyurea 100%
  • Antitumor 63%
  • Donor 46%
  • T-Lymphocytes 42%
  • Confidence Intervals 27%
  52 Citations (Scopus)

• Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators

  Sørensen, R. B., Hadrup, S. R., Svane, I. M., Hjortsø, M. C., Thor Straten, P., Andersen, M. H., Hjortsø, M. C. & Andersen, M. H., 17 Feb 2011, In: Blood. 117, 7, p. 2200-10 11 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Indoleamine-Pyrrole 2,3,-Dioxygenase 100%
  • Effector 80%
  • T-Lymphocytes 45%
  • Antigen 30%
  • Donor 25%
  84 Citations (Scopus)

• Possible benefits of the targeting of indoleamine 2,3-dioxygenase (IDO) in hepatitis B vaccination

  Straten, P. T. & Andersen, M. H., 12 May 2011, In: Vaccine. 29, 21, p. 3728

  Research output: Contribution to journal › Journal article › Research › peer-review

  1 Citation (Scopus)

• Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2

  Sørensen, R. B., Køllgaard, T., Andersen, R. S., van den Berg, J. H., Svane, I. M., Straten, P. T. & Andersen, M. H., 15 Mar 2011, In: Cancer Research. 71, 6, p. 2038-44 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Indoleamine-Pyrrole 2,3,-Dioxygenase 100%
  • T-Lymphocytes 45%
  • tryptophan methyl ester 41%
  • Neoplasms 23%
  • Stereoisomerism 17%
  38 Citations (Scopus)
• 2010

  Combined Treatment with Dendritic Cell Vaccine and Low-Dose Cyclophosphamide in Patients with Malignant Melanoma

  Engell-Noerregaard, L., Ellebaek, E., Buch-Hansen, T. Z., Nikolajsen, K., Straten, P. T., Andersen, M. H., Svane, I. M. & Andersen, M. H., 2010, In: Journal of Immunotherapy. 33, 8, p. 876-877 2 p.

  Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

• Increase of Circulating CD4(+)CD25(high)Foxp3(+) Regulatory T Cells in Patients With Metastatic Renal Cell Carcinoma During Treatment With Dendritic Cell Vaccination and Low-Dose Interleukin-2

  Berntsen, A., Brimnes, M. K., Straten, P. T., Svane, I. M., Berntsen, A., Brimnes, M. K., Straten, P. T. & Svane, I. M., 2010, In: Journal of Immunotherapy. 33, 4, p. 425-434 10 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

• Intratumoral Interleukin-21 Increases Antitumor Immunity, Tumor-infiltrating CD8(+) T-cell Density and Activity, and Enlarges Draining Lymph Nodes

  Sondergaard, H., Galsgaard, E. D., Bartholomaeussen, M., Straten, P. T., Odum, N. & Skak, K., Apr 2010, In: Journal of Immunotherapy. 33, 3, p. 236-249 14 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • interleukin-21 100%
  • Immunity 59%
  • Cell Count 54%
  • Lymph Nodes 51%
  • T-Lymphocytes 44%
  24 Citations (Scopus)

• Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes

  Søndergaard, H., Galsgaard, E. D., Bartholomaeussen, M., Straten, P. T., Ødum, N. & Skak, K., Apr 2010, In: Journal of Immunotherapy. 33, 3, p. 236-49 13 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • interleukin-21 100%
  • Immunity 59%
  • Cell Count 54%
  • Lymph Nodes 51%
  • T-Lymphocytes 44%
  24 Citations (Scopus)

• Spontaneous Cytotoxic T cell Reactivity Against IDO Exists in Cancer Patients and in Healthy Donors

  Sørensen, R. B., Straten, P. T., Andersen, M. H. & Andersen, M. H., 2010, In: Journal of Immunotherapy. 33, 8, p. 910-911 2 p.

  Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

• The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens

  Straten, P. T., Andersen, M. H. & Andersen, M. H., 1 Aug 2010, In: OncoTarget. 1, 4, p. 239-45 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Neoplasm Antigens 100%
  • Neoplasms 30%
  • Antigens 13%
  • Antisense Oligonucleotides 12%
  • Proteins 11%
  32 Citations (Scopus)

• Therapeutic cancer vaccines

  Larsen, S. K., Svane, I. M., Straten, P. T. & Andersen, M. H., 2010, In: Current Cancer Therapy Reviews. 6, 2, p. 163-174

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Cancer Vaccines 100%
  • Neoplasms 26%
  • Therapeutics 13%
  • Vaccination 13%
  • Immune System 13%
  2 Citations (Scopus)

• Therapeutic cancer vaccines in combination with conventional therapy

  Andersen, M. H., Junker, N., Ellebaek, E., Svane, I. M., Thor Straten, P. & Andersen, M. H., 1 Jan 2010, In: Journal of Biomedicine and Biotechnology. 2010, p. 237623

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Cancer Vaccines 100%
  • Protein 34%
  • Combination Drug Therapy 20%
  • Neoplasms 19%
  • Immunotherapy 18%
  24 Citations (Scopus)

• Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial

  Buch-Hansen, T. Z., Sørensen, R. B., Mellemgaard, A., Straten, P. T., Andersen, M. H., Svane, I. M. & Andersen, M. H., 2010, In: Journal of Immunotherapy. 33, 8, p. 919-920 2 p.

  Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

• Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

  Trepiakas, R., Berntsen, A., Hadrup, S. R., Bjørn, J., Geertsen, P. F., Straten, P. T., Andersen, M. H., Pedersen, A. E., Soleimani, A., Lorentzen, T., Johansen, J. S. & Svane, I. M., 1 Oct 2010, In: Cytotherapy. 12, 6, p. 721-34 14 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Neoplasm Antigens 100%
  • Dendritic Cells 84%
  • Melanoma 77%
  • Vaccination 75%
  • HLA-A2 Antigen 36%
  63 Citations (Scopus)
• 2009

  Adoptive cell transfer in the treatment of metastatic melanoma

  Straten, P. T. & Becker, J. C., 2009, In: Journal of Investigative Dermatology. 129, 12, p. 2743-5 3 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Adoptive Transfer 90%
  • Melanoma 65%
  • Cell- and Tissue-Based Therapy 49%
  • Interleukin-2 46%
  8 Citations (Scopus)